Insider Trading disclosures for Aeglea BioTherapeutics Inc

The latest disclosure was made by Cameron Turtle in Aeglea BioTherapeutics Inc where a trade of 277,750 Stock Option (Right to Buy) done was reported to US exchanges on Feb. 1, 2024.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Cameron Turtle	Director, Chief Executive Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	277,750	277,750	-		-	Stock Option (Right to Buy)
King-Jones Heidy	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	63,000	63,000	-		-	Stock Option (Right to Buy)
Scott Burrows L.	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	01 Feb 2024	70,000	70,000	-		-	Stock Option (Right to Buy)
Burrows L. Scott	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Dec 2023	134,953	134,953 (0%)	0%		0	Common Stock
W. Jeffrey Albers	Director		22 Nov 2023	34,360	34,360 (0%)	0%		0	Common Stock
Albers Jeffrey W.	Director		22 Nov 2023	859	0	-		-	Series A Preferred Stock
W. Jeffrey Albers	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Nov 2023	50,000	50,000	-		-	Stock Option (Right to Buy)
Magovcevic Ivana	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2023	1,950,000	1,950,000	-		-	Stock Option (right to buy)
Russell J. Cox	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2023	1,950,000	1,950,000	-		-	Stock Option (right to buy)
Alison F. Lawton	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2023	1,950,000	1,950,000	-		-	Stock Option (right to buy)
Hunter C. Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2023	1,950,000	1,950,000	-		-	Stock Option (right to buy)
Jonathan Alspaugh	President and CFO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	22 Jun 2023	19,787,969	19,787,969	-		-	Employee Stock Option (right to buy)
Linda Neuman	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	23 Feb 2023	550,000	550,000	-		-	Employee Stock Option (right to buy)
Michael Conick Hanley	Chief Business Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	23 Feb 2023	500,000	500,000	-		-	Employee Stock Option (right to buy)
James Paul Kastenmayer	General Counsel	Grant, award, or other acquisition of securities at price $ 0.00 per share.	23 Feb 2023	500,000	500,000	-		-	Employee Stock Option (right to buy)
Jonathan Alspaugh	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	23 Feb 2023	640,000	640,000	-		-	Employee Stock Option (right to buy)
Jeffrey M. Goldberg	Director, President and CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	29 Nov 2022	1,884,838	1,884,838	-		-	Employee Stock Option (right to buy)
Linda Neuman	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	14 Nov 2022	25,000	25,000	-		-	Employee Stock Option (right to buy)
Marcio Souza	Director	Purchase of securities on an exchange or from another person at price $ 0.56 per share.	25 Aug 2022	90,000	90,000 (0%)	0%	0.6	50,472	Common Stock
Leslie Sloan	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	23 Aug 2022	130,000	130,000	-		-	Employee Stock Option (right to buy)
Michael Conick Hanley	Chief Business Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	23 Aug 2022	130,000	130,000	-		-	Employee Stock Option (right to buy)
James Paul Kastenmayer	Interim CEO & General Counsel	Grant, award, or other acquisition of securities at price $ 0.00 per share.	23 Aug 2022	130,000	130,000	-		-	Employee Stock Option (right to buy)
Jonathan Alspaugh	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	23 Aug 2022	130,000	130,000	-		-	Employee Stock Option (right to buy)
Michael Conick Hanley	Chief Commercial Officer	Purchase of securities on an exchange or from another person at price $ 0.71 per share.	08 Jun 2022	28,200	36,200 (0%)	0%	0.7	20,022	Common Stock
Magovcevic Ivana	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2022	43,000	43,000	-		-	Director Stock Option (right to buy)
V. Bryan Lawlis	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2022	43,000	43,000	-		-	Director Stock Option (right to buy)
Russell J. Cox	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2022	43,000	43,000	-		-	Director Stock Option (right to buy)
Alison F. Lawton	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2022	43,000	43,000	-		-	Director Stock Option (right to buy)
Sandesh Mahatme	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2022	43,000	43,000	-		-	Director Stock Option (right to buy)
Hunter C. Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2022	43,000	43,000	-		-	Director Stock Option (right to buy)
Armen Shanafelt	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2022	43,000	43,000	-		-	Director Stock Option (right to buy)
Marcio Souza	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	07 Jun 2022	43,000	43,000	-		-	Director Stock Option (right to buy)
Anthony G. Quinn	Director, President & CEO	Purchase of securities on an exchange or from another person at price $ 2.34 per share.	16 Mar 2022	80,079	550,540 (1%)	0%	2.3	187,705	Common Stock
Anthony G. Quinn	Director, President & CEO	Purchase of securities on an exchange or from another person at price $ 1.93 per share.	11 Mar 2022	67,472	431,044 (1%)	0%	1.9	130,221	Common Stock
Anthony G. Quinn	Director, President & CEO	Purchase of securities on an exchange or from another person at price $ 2.06 per share.	11 Mar 2022	34,777	363,572 (1%)	0%	2.1	71,780	Common Stock
Anthony G. Quinn	Director, President & CEO	Purchase of securities on an exchange or from another person at price $ 1.86 per share.	11 Mar 2022	42,417	473,461 (1%)	0%	1.9	78,942	Common Stock
Jonathan Alspaugh	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 2.08 per share.	11 Mar 2022	75,000	165,372 (0%)	0%	2.1	156,000	Common Stock
Anthony G. Quinn	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Feb 2022	350,000	350,000	-		-	Employee Stock Option (right to buy)
Leslie Sloan	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Feb 2022	180,000	180,000	-		-	Employee Stock Option (right to buy)
Michael Conick Hanley	Chief Commercial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Feb 2022	160,000	160,000	-		-	Employee Stock Option (right to buy)
Steven Weber	VP, Controller&Princ Acctg Off	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Feb 2022	30,000	30,000	-		-	Employee Stock Option (right to buy)
Jonathan Alspaugh	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	17 Feb 2022	170,000	170,000	-		-	Employee Stock Option (right to buy)
Anthony G. Quinn	Director, President & CEO	Purchase of securities on an exchange or from another person at price $ 3.70 per share.	09 Dec 2021	43,108	318,269 (1%)	0%	3.7	159,500	Common Stock
Anthony G. Quinn	Director, President & CEO	Purchase of securities on an exchange or from another person at price $ 3.75 per share.	09 Dec 2021	10,526	328,795 (1%)	0%	3.8	39,473	Common Stock
Armen Shanafelt	Director	Purchase of securities on an exchange or from another person at price $ 3.65 per share.	09 Dec 2021	14,685	150,000 (0%)	0%	3.6	53,600	Common Stock
Armen Shanafelt	Director	Purchase of securities on an exchange or from another person at price $ 3.65 per share.	09 Dec 2021	13,516	135,315 (0%)	0%	3.6	49,333	Common Stock
Armen Shanafelt	Director	Purchase of securities on an exchange or from another person at price $ 3.67 per share.	09 Dec 2021	121,799	121,799 (0%)	0%	3.7	446,759	Common Stock
Jonathan Alspaugh	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 3.72 per share.	09 Dec 2021	50,000	90,372 (0%)	0%	3.7	186,000	Common Stock
Hunter C. Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Nov 2021	60,000	60,000	-		-	Director Stock Option (right to buy)
Jonathan Alspaugh	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 6.37 per share.	16 Aug 2021	9,780	9,780 (0%)	0%	6.4	62,275	Common Stock

Showing 1 to 50 of 185 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

New 52W High today

Insider Trading disclosures for Aeglea BioTherapeutics Inc

The latest disclosure was made by Cameron Turtle in Aeglea BioTherapeutics Inc where a trade of 277,750 Stock Option (Right to Buy) done was reported to US exchanges on Feb. 1, 2024.

Screeners based on Insider Trading and SAST parameters